Haloperidol half-life after chronic dosing

Journal of Clinical Psychopharmacology

Volumn 24, Issue 6, 2004, Pages 656-660

  De Leon, Jose ^a   Diaz, Francisco J ^b   Wedlund, Peter ^a   Josiassen, Richard C ^c,d   Cooper, Thomas B ^e,f   Simpson, George M ^g  

^a EASTERN STATE HOSPITAL   (United States)

^b UNIVERSIDAD NACIONAL DE COLOMBIA   (Colombia)

^c Arthur P Noyes Research Foundation   (United States)

^d UNIVERSITY OF PENNSYLVANIA   (United States)

^e NATHAN S KLINE INSTITUTE FOR PSYCHIATRIC RESEARCH   (United States)

^f NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

^g UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOCHROME P450 2D6; CYTOCHROME P450 3A5; HALOPERIDOL;

ADULT; AFRICAN AMERICAN; AGE; ARTICLE; BODY WEIGHT; CLINICAL ARTICLE; CONTROLLED STUDY; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG HALF LIFE; FEMALE; GENDER; GENOTYPE; HUMAN; MALE; PRIORITY JOURNAL; RACE; SMOKING;

ADULT; CYTOCHROME P-450 CYP2D6; CYTOCHROME P-450 ENZYME SYSTEM; DOUBLE-BLIND METHOD; FEMALE; HALF-LIFE; HALOPERIDOL; HUMANS; MALE; MIDDLE AGED; SCHIZOPHRENIA; STATISTICS, NONPARAMETRIC;

EID: 8744274006     PISSN: 02710749     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.jcp.0000145340.53417.ca     Document Type: Article

References (21)

1. American Medical Association. Drug Evaluations Annual 1993. Milwaukee: American Medical Association; 1993.
2. Kudo S, Ishizaki T. Pharmacokinetics of haloperidol an update. Clin Pharmacokinet. 1999;37:435-456.
3. Campbell A, Baldessarini RJ. Prolonged pharmacologic activity of neuroleptics [letter]. Arch Gen Psychiatry. 1985;42:637.
4. Sramek J, Herrera J, Costa J, et al. Persistence of plasma neuroleptic levels after drug discontinuation [letter]. J Clin Psychopharmacol. 1987;7:436-437.
5. Khot V, DeVane CL, Korpi ER, et al. The assessment and clinical implications of haloperidol acute-dose, steady-state, and withdrawal pharmacokinetics. J Clin Psychopharmacol. 1993;13:120-127.
6. Midha KK, Chakraborty BS, Ganes DA, et al. Intersubject variation in the pharmacokinetics of haloperidol and reduced haloperidol. J Clin Psychopharmacol. 1989;9:98-104.
7. Ereshefsky L, Davis CM, Harrington CA, et al. Haloperidol and reduced haloperidol plasma levels in selected schizophrenia patients. J Clin Psychopharmacol. 1984;4:138-142.
8. Jann MW, Wen-Ho C, Hsien-Yuan L. Differences in haloperidol epidemiologic pharmacokinetic studies [letter]. J Clin Psychopharmacol. 2001;21:628-629.
9. de Leon J. Glucuronidation enzyme genes and psychiatry. Int J Neuropsychopharmacol. 2003;6:57-72.
10. Kuel P, Zhang J, Lin Y, et al. Sequence diversity in CYP3A promoters and characterization of the genetic basis of polymorphic CYP3A5 expression. Nat Genet. 2001;27:383-391.
11. Llerena A, Dahl ML, Ekqvist B, et al. Haloperidol disposition is dependent on the debrisoquine hydroxylation phenotype: increased plasma levels of the reduced metabolite in poor metabolizers. Ther Drug Monit. 1992;14:261-264.
12. Llerena A, Alm C, Dahl ML, et al. Haloperidol disposition is dependent on debrisoquine hydroxylation phenotype. Ther Drug Monit. 1992;14:92-97.
13. Pan L, Stichele RV, Rosseel MT, et al. Effects of smoking, CYP2D6 genotype, and concomitant drug intake on the steady state plasma concentrations of haloperidol and reduced haloperidol in schizophrenic inpatients. Ther Drug Monit. 1999;21:489-497.
14. Simpson GM, Josiassen RC, Stanilla JK, et al. Double-blind study of clozapine dose response in chronic schizophrenia. Am J Psychiatry. 1999;156:1744-1750.
15. Kane JM, Honigfeld G, Singer J, et al. Clozapine for the treatment-resistant schizophrenic. A double-blind comparison with chlorpromazine. Arch Gen Psychiatry. 1988;45:789-796.
16. Devanand DP, Marder K, Michaels KS, et al. A randomized, placebo-controlled dose-comparison trial of haloperidol for psychosis and disruptive behaviors in Alzheimer's disease. Am J Psychiatry. 1998;155:1512-1520.
17. Chen S, Chou W, Blouin R, et al. Clinical and practical aspects to screening for the cytochrome P450-2D6 (CYP2D6) enzyme polymorphism. Clin Pharmacol Ther. 1996;60:522-534.
18. Chou WH, Yan FX, Robbins-Weilert DK, et al. Comparison of two CYP2D6 genotyping methods and assessments of genotype-phenotype relationships. Clin Chem. 2003;49:542-551.
19. Simpson GM, Yadalam KG, Levinson DF, et al. Single-dose pharmacokinetics of fluphenazine after fluphenazine decanoate administration. J Clin Psychopharmacol. 1990;10:417-421.
20. Potkin SG, Thyrum PT, Alva G, et al. The safety and pharmacokinetics of quetiapine when coadministered with haloperidol, risperidone, or thioridazine. J Clin Psychopharmacol. 2002;22:121-130.
21. Simpson GM, Amuso D, Blair JH, et al. Phenothiazine-produced extrapyramidal system disturbance. Arch Gen Psychiatry. 1964;10:199-208.